CN1045777C - 四环衍生物,制备方法和用途 - Google Patents

四环衍生物,制备方法和用途 Download PDF

Info

Publication number
CN1045777C
CN1045777C CN95192078A CN95192078A CN1045777C CN 1045777 C CN1045777 C CN 1045777C CN 95192078 A CN95192078 A CN 95192078A CN 95192078 A CN95192078 A CN 95192078A CN 1045777 C CN1045777 C CN 1045777C
Authority
CN
China
Prior art keywords
pyrido
alkyl
compound
cis
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN95192078A
Other languages
English (en)
Chinese (zh)
Other versions
CN1143963A (zh
Inventor
A·C·－M·道根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Laboratoire Glaxo Wellcome SA
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1045777(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoire Glaxo Wellcome SA, Icos Corp filed Critical Laboratoire Glaxo Wellcome SA
Publication of CN1143963A publication Critical patent/CN1143963A/zh
Application granted granted Critical
Publication of CN1045777C publication Critical patent/CN1045777C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN95192078A 1994-01-21 1995-01-19 四环衍生物,制备方法和用途 Expired - Lifetime CN1045777C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9401090.7 1994-01-21
GB9401090A GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN98122779A Division CN1070492C (zh) 1994-01-21 1998-12-01 四环衍生物,制备方法和用途

Publications (2)

Publication Number Publication Date
CN1143963A CN1143963A (zh) 1997-02-26
CN1045777C true CN1045777C (zh) 1999-10-20

Family

ID=10749089

Family Applications (2)

Application Number Title Priority Date Filing Date
CN95192078A Expired - Lifetime CN1045777C (zh) 1994-01-21 1995-01-19 四环衍生物,制备方法和用途
CN98122779A Expired - Lifetime CN1070492C (zh) 1994-01-21 1998-12-01 四环衍生物,制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN98122779A Expired - Lifetime CN1070492C (zh) 1994-01-21 1998-12-01 四环衍生物,制备方法和用途

Country Status (48)

Country Link
US (5) US5859006A (https=)
EP (1) EP0740668B1 (https=)
JP (3) JP3808095B2 (https=)
KR (1) KR100357411B1 (https=)
CN (2) CN1045777C (https=)
AP (1) AP556A (https=)
AT (1) ATE169018T1 (https=)
AU (2) AU689205B2 (https=)
BG (1) BG62733B1 (https=)
BR (1) BR9506559C8 (https=)
CA (1) CA2181377C (https=)
CO (1) CO4340684A1 (https=)
CZ (1) CZ286566B6 (https=)
DE (2) DE10399006I2 (https=)
DK (1) DK0740668T3 (https=)
EE (1) EE03231B1 (https=)
EG (1) EG25852A (https=)
ES (1) ES2122543T3 (https=)
FI (1) FI113176B (https=)
GB (1) GB9401090D0 (https=)
HR (1) HRP950023B1 (https=)
HU (1) HU222494B1 (https=)
IL (1) IL112384A (https=)
IN (1) IN183942B (https=)
IS (1) IS1888B (https=)
LU (1) LU91017I2 (https=)
LV (1) LV11690B (https=)
MA (1) MA23433A1 (https=)
MX (1) MX9602904A (https=)
MY (1) MY114663A (https=)
NL (1) NL300124I2 (https=)
NO (2) NO306465B1 (https=)
NZ (1) NZ279199A (https=)
OA (1) OA10584A (https=)
PE (1) PE49495A1 (https=)
PL (1) PL179744B1 (https=)
RO (1) RO117794B1 (https=)
RU (1) RU2142463C1 (https=)
SA (1) SA95150475B1 (https=)
SG (1) SG49184A1 (https=)
SI (1) SI0740668T1 (https=)
SK (1) SK280879B6 (https=)
SV (1) SV1995000002A (https=)
TN (1) TNSN95004A1 (https=)
TW (1) TW378210B (https=)
UY (1) UY23893A1 (https=)
WO (1) WO1995019978A1 (https=)
ZA (1) ZA95424B (https=)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US5874440A (en) 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6046216A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
BR9709230A (pt) * 1996-05-10 1999-08-10 Icos Corp Composto
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6071934A (en) 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
AU756136B2 (en) 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6211220B1 (en) 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
CA2367138C (en) 1999-03-24 2010-10-05 Alejandro M. S. Mayer Anti-inflammatory uses of manzamines
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
PT1200090E (pt) 1999-08-03 2013-11-25 Icos Corp Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
US6562830B1 (en) 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20020006926A1 (en) 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
JP2004501124A (ja) * 2000-06-07 2004-01-15 リリー　アイコス　リミテッド　ライアビリティ　カンパニー 化合物
MXPA02012470A (es) * 2000-06-23 2004-01-26 Lilly Icos Llc Inhibidores de fosfodiesterasa especificos para gmp ciclico.
US6911542B2 (en) 2000-06-23 2005-06-28 Lilly Icos Llc. Pyrazino[1′,2′:1,6]pyrido[3,4b]indole derivatives
MXPA02012659A (es) * 2000-06-26 2003-09-22 Lilly Icos Llc Derivados de pirazindiona condensados.
MXPA03000688A (es) * 2000-07-24 2004-11-01 Bayer Cropscience Ag Bifenilcarboxiamidas.
WO2002010166A1 (en) * 2000-08-02 2002-02-07 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6962918B2 (en) 2000-10-02 2005-11-08 Lilly Icos Llc. Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
CA2423308A1 (en) 2000-10-02 2002-04-11 Lilly Icos Llc Condensed pyridoindole derivatives
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
EP1211313A3 (en) * 2000-11-01 2003-04-23 Pfizer Limited Modulation of PDE11A activity
ATE337320T1 (de) 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
EP1383765B1 (en) * 2001-04-25 2006-12-13 Lilly Icos LLC Carboline derivatives as inhibitors of phosphodiesterase 5 (PDE5) for the treatment of cardiovascular diseases and erectile dysfunction
FR2824829B1 (fr) * 2001-05-16 2005-06-03 Macef Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
ATE360422T1 (de) * 2001-06-05 2007-05-15 Lilly Icos Llc Tetrazyklische verbindungen als pde5-inhibitoren
ES2307758T3 (es) 2001-06-05 2008-12-01 Lilly Icos Llc Derivados de pirazino (1',2':1,6)pirido(3,4-b)indol 1,4-diona.
EP1401835A1 (en) * 2001-06-05 2004-03-31 Lilly Icos LLC Carboline derivatives as pde-5 inhibitors
DE60213798T2 (de) * 2001-06-21 2007-08-16 Lilly Icos Llc, Wilmington Carbolinderivate als pdev inhibitoren
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
ES2289159T3 (es) 2001-11-14 2008-02-01 Ortho-Mcneil Pharmaceutical Corporation Derivados tetraciclicos sustituidos de pirroloquinolona utilizados como inhibidores de fosfodiesterasa.
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2485984A1 (en) * 2002-05-23 2003-12-04 Pfizer Inc. Pharmaceutical combination of pde5 inhibitors with ace inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
NZ537784A (en) * 2002-07-31 2008-01-31 Lilly Icos Llc Modified Pictet-Spengler reaction and products prepared therefrom
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
CA2525946C (en) 2003-05-22 2013-01-29 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
JP2007501866A (ja) * 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1699436A2 (en) * 2003-12-12 2006-09-13 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2005068464A2 (en) * 2003-12-15 2005-07-28 Cadila Healthcare Limited Process for preparing tadalafil and its intermediates
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CA2560528A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
JP2007530566A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド （ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
CA2562251C (en) 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
WO2005116030A1 (en) * 2004-05-31 2005-12-08 Matrix Laboratories Ltd A process for the preparation of tadalafil
EP1776108A1 (en) * 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
EP2216329A1 (en) * 2004-10-28 2010-08-11 Dr. Reddy's Laboratories Ltd. Processes for the preparation of tadalafi
KR20070072891A (ko) * 2004-11-02 2007-07-06 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 결정형 및 이의 제조 방법
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1829874B1 (en) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
EP1851222A1 (en) * 2005-02-25 2007-11-07 Teva Pharmaceutical Industries Ltd Process of synthesizing tadalafil
MX2007010431A (es) * 2005-02-25 2007-10-11 Teva Pharma Proceso para purificar tadalafil.
US7417044B2 (en) 2005-02-25 2008-08-26 Teva Pharmaceutical Industries Ltd. Tadalafil having a large particle size and a process for preparation thereof
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
US20060276652A1 (en) * 2005-04-12 2006-12-07 Ben-Zion Dolitzky Preparation of tadalafil intermediates
JP2008536888A (ja) 2005-04-19 2008-09-11 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺高血圧症の治療のためのロフルミラスト
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
AU2006275702A1 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
WO2007100387A2 (en) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Process for preparing tadalafil
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US7201929B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
EP2004644A1 (en) * 2006-03-24 2008-12-24 Glenmark Pharmaceuticals Limited Process for the preparation of tadalafil
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
KR101140110B1 (ko) * 2006-07-07 2012-06-04 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물
PT2046292E (pt) 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
HUE025355T2 (en) 2006-12-12 2016-02-29 Gilead Sciences Inc Composition for treating pulmonary hypertension
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
CN101674728A (zh) 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
CA2677690C (en) 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
WO2008103470A2 (en) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
US20090098211A1 (en) * 2007-04-25 2009-04-16 Ilan Zalit Solid dosage forms
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DK2170880T3 (da) 2007-06-29 2012-09-10 Ranbaxy Lab Ltd Fremgangsmåde til fremstillingen af mellemprodukter af tetracycliske forbindelser
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
ITMI20080285A1 (it) * 2008-02-22 2009-08-23 Endura Spa Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
EP2107059A1 (en) 2008-03-31 2009-10-07 LEK Pharmaceuticals D.D. Conversion of tryptophan into ß-carboline derivatives
PL385356A1 (pl) 2008-06-03 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania tadalafilu
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2181997A1 (en) 2008-10-30 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of tadalafil
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8586587B2 (en) 2009-02-26 2013-11-19 Thar Pharmaceuticals, Inc. Crystalline molecular complex of tadalafil and methylparaben
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
JP2013523809A (ja) 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
MX346730B (es) 2010-10-15 2017-03-30 Gilead Sciences Inc Composiciones y metodos para el tratamiento de la hipertension pulmonar.
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
EP2673275B1 (en) 2011-02-10 2015-04-08 Interquim, S.A. Process for obtaining compounds derived from tetrahydro-beta-carboline
US20120123124A1 (en) * 2011-04-22 2012-05-17 Drug Process Licensing Associates, LLC Manufacturing process for Tadalafil from racemic or L-tryptophan
CN102180876B (zh) * 2011-05-28 2016-05-18 浙江华海药业股份有限公司 一种他达那非晶型i的制备方法
EP2535049A1 (en) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil for the treatment of dementia
CN102367253B (zh) * 2011-09-20 2016-04-06 浙江华海药业股份有限公司 一种制备他达拉非晶型a的方法
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
WO2013109223A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
WO2013109225A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical tablet formulations comprising ceftibuten
WO2014092661A1 (en) 2012-01-18 2014-06-19 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
CA2864322C (en) 2012-02-28 2016-08-09 Seoul Pharma. Co., Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
WO2014088326A1 (ko) 2012-12-04 2014-06-12 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
ES2882258T3 (es) 2012-12-21 2021-12-01 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
MX2015010725A (es) 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
CN103232451A (zh) * 2013-05-14 2013-08-07 张家港威胜生物医药有限公司 一种他达那非的简易制备工艺
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
EP2962684A1 (en) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Orally disintegrating formulations of tadalafil
ES2784251T3 (es) 2014-06-30 2020-09-23 Montero Gida Sanayi Ve Ticaret As Formulaciones de disgregación por vía oral de tadalafilo
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
SI3172207T1 (sl) 2014-07-23 2019-06-28 Krka D.D., Novo Mesto Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
AU2015399642B2 (en) 2015-06-26 2020-04-09 Chongqing Dikang Erle Pharma Co. Ltd. Novel phosphodiesterase type-5 inhibitor and application thereof
CN105541840B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 关键中间体及其合成方法和在制备他达拉非方面的应用
CN105541835B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
CN106977516B (zh) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 一种他达拉非的制备方法
KR20210150495A (ko) 2019-04-10 2021-12-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료
RU2692764C1 (ru) 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила
CN111995658B (zh) * 2019-05-27 2022-08-02 首都医科大学 Ldv修饰的五环哌嗪二酮及其制备和应用
JP2022540866A (ja) 2019-07-15 2022-09-20 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． ３－（ベンゾ［ｄ］［１，３］ジオキサゾール－５－イル）－７－（１－ヒドロキシプロパン－２－イル）－１－（１Ｈ－インドール－３－イル）－６，７－ジヒドロ－３Ｈ－オキサゾール［３，４－ａ］ピラジン－５，８－ジオン化合物の立体異性体およびその抗腫瘍剤およびホスホジエステラーゼ酵素阻害剤としての使用
CN110606847A (zh) * 2019-07-30 2019-12-24 中国医药集团总公司四川抗菌素工业研究所 一种他达拉非顺式中间体的制备方法及其应用
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR20240117491A (ko) 2023-01-25 2024-08-01 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물
JP2026510233A (ja) 2023-02-16 2026-04-02 ユニバーシティー オブ ロチェスター グリンパ－リンパ流出の改善
CN116715667A (zh) * 2023-06-20 2023-09-08 常州制药厂有限公司 一种他达拉非新晶型b及其制备方法
EP4684777A1 (en) 2024-07-24 2026-01-28 Adalvo Limited A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEM.PHARM.BVLL 1985. 1. 1 ISHIDA 等 *
J.INED.CHEM 1973. 1. 1 SAXENA of ocl *

Also Published As

Publication number Publication date
UY23893A1 (es) 1995-07-11
US5859006A (en) 1999-01-12
RO117794B1 (ro) 2002-07-30
NL300124I1 (nl) 2003-07-01
BG100727A (bg) 1997-02-28
CN1070492C (zh) 2001-09-05
US6784179B2 (en) 2004-08-31
PL179744B1 (pl) 2000-10-31
US20020119976A1 (en) 2002-08-29
IN183942B (https=) 2000-05-20
AU689205B2 (en) 1998-03-26
JP2004217674A (ja) 2004-08-05
DE69503753D1 (de) 1998-09-03
EE03231B1 (et) 1999-10-15
FI962927A0 (fi) 1996-07-19
US6025494A (en) 2000-02-15
BG62733B1 (bg) 2000-06-30
HRP950023B1 (en) 2000-10-31
CZ286566B6 (cs) 2000-05-17
SG49184A1 (en) 1998-05-18
EG25852A (en) 2012-09-10
NL300124I2 (nl) 2003-11-03
AU1574895A (en) 1995-08-08
NO963015L (no) 1996-09-09
IL112384A0 (en) 1995-03-30
JP2009102386A (ja) 2009-05-14
NO2003002I1 (no) 2003-01-22
IS4252A (is) 1995-07-22
AU707055B2 (en) 1999-07-01
EP0740668B1 (en) 1998-07-29
AP9500712A0 (en) 1995-01-31
US6369059B1 (en) 2002-04-09
CZ211696A3 (en) 1997-06-11
NO2003002I2 (no) 2005-03-21
ZA95424B (en) 1995-09-27
PE49495A1 (es) 1996-01-10
IL112384A (en) 1998-08-16
DE10399006I2 (de) 2004-05-06
BR9506559A (pt) 1997-10-28
SK280879B6 (sk) 2000-08-14
HU222494B1 (hu) 2003-07-28
MX9602904A (es) 1997-12-31
DE69503753T2 (de) 1999-01-21
HRP950023A2 (en) 1998-04-30
DK0740668T3 (da) 1999-05-03
GB9401090D0 (en) 1994-03-16
TNSN95004A1 (fr) 1996-02-06
JP3808095B2 (ja) 2006-08-09
CN1224720A (zh) 1999-08-04
MA23433A1 (fr) 1995-10-01
AU7391298A (en) 1998-08-20
SI0740668T1 (en) 1999-02-28
DE10399006I1 (de) 2003-07-31
WO1995019978A1 (en) 1995-07-27
RU2142463C1 (ru) 1999-12-10
FI113176B (fi) 2004-03-15
PL315559A1 (en) 1996-11-12
FI962927A7 (fi) 1996-07-19
JP4347125B2 (ja) 2009-10-21
BR9506559C8 (pt) 2020-07-07
US6127542A (en) 2000-10-03
LV11690A (lv) 1997-02-20
LU91017I2 (fr) 2003-05-26
NO306465B1 (no) 1999-11-08
LV11690B (en) 1997-06-20
HK1013286A1 (en) 1999-08-20
CO4340684A1 (es) 1996-07-30
SV1995000002A (es) 1995-10-04
KR100357411B1 (ko) 2003-02-05
CN1143963A (zh) 1997-02-26
JPH09508113A (ja) 1997-08-19
NZ279199A (en) 1998-01-26
CA2181377C (en) 2002-05-28
IS1888B (is) 2003-09-01
SK94096A3 (en) 1997-04-09
ES2122543T3 (es) 1998-12-16
CA2181377A1 (en) 1995-07-27
HUT74943A (en) 1997-03-28
HU9601982D0 (en) 1996-09-30
SA95150475B1 (ar) 2005-07-31
TW378210B (en) 2000-01-01
AP556A (en) 1996-11-07
MY114663A (en) 2002-12-31
OA10584A (en) 2002-08-26
NO963015D0 (no) 1996-07-19
ATE169018T1 (de) 1998-08-15
EP0740668A1 (en) 1996-11-06

Similar Documents

Publication Publication Date Title
CN1045777C (zh) 四环衍生物,制备方法和用途
CN1041090C (zh) 吡啶并嘧啶衍生物及其制备和用途
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CN1161341C (zh) cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
CN1764641A (zh) 病毒聚合酶抑制剂
CN1179960C (zh) 吲哚衍生物和其在治疗骨质疏松中的应用以及其它应用
CN1036995C (zh) 咪唑并二氮杂䓬及其制备方法和用途
CN1713910A (zh) 作为p38激酶抑制剂的氮杂吲哚衍生物
CN1320037A (zh) 抗病毒的吲哚氧代乙酰基哌嗪衍生物
CN1906190A (zh) 选择性激酶抑制剂
CN1585749A (zh) 类大麻苷受体配体
CN1468216A (zh) 含氮五员环化合物
CN1802373A (zh) 作为激酶抑制剂的吡唑并异喹啉衍生物
CN1657523A (zh) 环状化合物
CN1444563A (zh) 喹啉和喹唑啉衍生物
CN1829711A (zh) 用于治疗炎性和过敏性病症的新杂环化合物、其制备方法和含有它们的药物组合物
CN1705647A (zh) 用于治疗或预防糖尿病的β－氨基杂环二肽酰肽酶抑制剂
CN1255133A (zh) 1,5－二氢－吡唑并[3,4－d]－嘧啶酮衍生物
CN1420889A (zh) 具有药物活性的二氢异吲哚衍生物
CN1216531A (zh) 用作内皮缩血管肽受体拮抗剂的吲哚衍生物
CN1491225A (zh) 三杂环化合物和包括其作为活性组分的药物
CN1454211A (zh) 作为Xa因子抑制剂的含氮杂双环化合物
CN1681789A (zh) 1－吡啶－4－基－脲衍生物
CN1297442A (zh) 用作抗癌剂和抗增殖剂的5－氨基茚并[1,2－c]吡唑－4－酮类化合物
CN1119856A (zh) Hiv逆转录酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Washington State

Applicant after: Icos Corp.

Address before: France

Applicant before: Laboratoires Glaxo S. A.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: LABORATOIRES GLAXO S.A. TO: ICOS CORPORATION

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ELI LILLY COMPANY

Free format text: FORMER OWNER: ICOS CORPORATION

Effective date: 20070921

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20070921

Address after: indiana

Patentee after: Eli Lilly and Co.

Address before: Washington State

Patentee before: Icos Corp.

C56 Change in the name or address of the patentee

Owner name: LILLY CO., ELI.

Free format text: FORMER NAME: ELI LILLY AND CO.

CP03 Change of name, title or address

Address after: indiana

Patentee after: Lilly Co., Eli.

Address before: Indiana, USA

Patentee before: Eli Lilly and Co.

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20150119

Granted publication date: 19991020